1/18 Fig. 1a






Fig. 1b




2/18 Fig. 2




Fluorescence intensity

Fig. 3




BEST AVAILABLE COPY


3/18 Fig. 4




Effector: Target ratio


4/18 Fig. 5







5/18 Fig. 6






6/18 Fig. 7






7/18 Fig. 8




BEST AVAILABLE COPY


Rec'd PCT/PTO 14 JAN 2005

8/18 Fig. 9



9/17 Fig. 10





Days after Her-2/CT26 transfer

10/18 Fig. 11






Fig. 12a




11/18 Fig. 12b

Her2-CT26



CT26



E: T ratio

Rec'd PCT/PTO 14 JAN 2005

12/18 Fig. 13a






Fig. 13b




13/18 Fig. 13c



Days after Her2-CT26 challagne

Fig. 13d



Days after Her2-CT26 challagne

14/18 Fig. 14a






Fig. 14b




15/18 Fig. 14c



Days after tumor challagne

Fig. 15a



16/18 Fig. 15b






Fig. 15c




PCT/KR2003/001400

Rec'd PCT/PTO 14 JAN 2005

17/18 Fig. 15d



Days after Her2-CT26 transfer



Days after Her2-CT26 transfer

18/18 Fig. 16

